ABT-089, A Neuronal Nicotinic Receptor Partial Agonist, for the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Pilot Study

Biological Psychiatry

Volumn 59, Issue 11, 2006, Pages 1065-1070

  Wilens, Timothy E ^a   Verlinden, Marleen H ^b   Adler, Lenard A ^c   Wozniak, Patricia J ^b   West, Scott A ^d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b ABBOTT LABORATORIES   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CNS Healthcare   (United States)

Author keywords

ADHD; Adult; nicotinic receptor agonist; pharmacology; pilot study; treatment

Indexed keywords

2 METHYL 3 (2 PYRROLIDINYLMETHOXY)PYRIDINE; NICOTINIC AGENT; PLACEBO;

ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INCREASED APPETITE; MALE; METHODOLOGY; NERVOUSNESS; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SOMNOLENCE; TREATMENT OUTCOME;

ADULT; ATTENTION; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; COGNITION; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MEMORY, SHORT-TERM; NEUROPSYCHOLOGICAL TESTS; NICOTINIC AGONISTS; PILOT PROJECTS; PSYCHIATRIC STATUS RATING SCALES; PYRIDINES; PYRROLIDINES; TREATMENT OUTCOME;

EID: 33744903636     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2005.10.029     Document Type: Article

References (32)

1. Barkley R. Major life activity and health outcomes associated with attention-deficit hyperactivity disorder. J Clin Psychiatry 63 (2002) 10-15
2. Barkley R.A., Fischer M., Smallish L., and Fletcher K. The persistence of attention-deficity/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder. J Abnorm Psychol 111 (2002) 279-289
3. Biederman J. Impact of comorbidity in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 65 (2004) 3-7
4. Biederman J., Mick E., and Faraone S.V. Age-dependent decline of symptoms of attention deficit hyperactivity disorder. Impact of remission definition and symptom type. Am J Psychiatry 157 (2000) 816-818
5. Conners C., Levin E.D., Sparrow E., Hinton S.C., Erhardt D., Meck W.H., et al. Nicotine and attention deficit hyperactivity disorder (ADHD). Psychopharmocol Bull 32 (1996) 67-73
6. Conners C.K. The Continuous Performance Test (1995), Multi-Health Systems, Toronto, Canada
7. Conners C.K., Erhardt D., and Sparrow E. Conners' Adult ADHD Rating Scales (CAARS) (1999), Multi-Health Systems, North Tonawanda, New York
8. Decker M.W., Bannon A.W., Curzon P., Gunther K.L., Brioni J.D., Holladay M.W., et al. ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy) pyridine dihydrochloride]: II. A novel cholinergic channel modulator with effects on cognitive performance in rats and monkeys. J Pharmacol Exp Ther 283 (1997) 247-258
9. Faraone S.V., Perlis R.H., Doyle A.E., Smoller J.W., Goralnick J.J., Holmgren M.A., et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry 57 (2005) 1313-1323
10. Faraone S.V., Sergeant J., Gillberg C., and Biederman J. The worldwide prevalence of ADHD. Is it an American condition?. World Psychiatry 2 (2003) 104-113
11. Geller B., Warner K., Williams M., and Zimerman B. Prepubertal and young adolescent bipolarity versus ADHD. Assessment and validity using the WASH-U-KSADS, CBCL and TRF. J Affect Disord 51 (1998) 93-100
12. Guy W. Clinical Global Impressions. Early Clinical Drug Evaluation Unit (ECDEU) Assessment Manual for Psychopharmacology. DHEW publication no. ADM 76-338 (1976), National Institute of Mental Health, Rockville, Maryland 218-222
13. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 32 (1959) 50-55
14. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 23 (1960) 56-62
15. Jensen A.R., and Rohwer W.D. The Stroop color word test. A review. Acta Psychol 25 (1966) 36-93
16. Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O, et al (in press): The prevalence and correlates of adult ADHD in the United States: Results from the national comorbidity survey replication. Am J Psychiatry.
17. Levin E.D., Conners C.K., Sparrow E., Hinton S.C., Erhardt D., Meck W.H., et al. Nicotine effects on adults with attention-deficit/hyperactivity disorder. Psychopharmacology 123 (1996) 55-63
18. Michelson D., Adler L., Spencer T., Reimherr F.W., West S.A., Allen A.J., et al. Atomoxetine in adults with ADHD. Two randomized, placebo-controlled studies. Biol Psychiatry 53 (2003) 112-120
19. Millstein R., Wilens T., Biederman J., and Spencer T. Presenting ADHD symptoms and subtypes in clinically referred adults with ADHD. J Attent Disord 2 (1997) 159-166
20. Newhouse P.A., Potter A., and Singh A. Effects of nicotinic stimulation on cognitive performance. Curr Opin Pharmacol 4 (2004) 36-46
21. Orvaschel H. Psychiatric interviews suitable for use in research with children and adolescents. Psychopharmacol Bull 21 (1985) 737-745
22. Rueter L.E., Anderson D.J., Briggs C.A., Donnelly-Roberts D.L., Gintant G.A., Gopalakrishnan M., et al. ABT-089. Pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders. CNS Drug Rev 10 (2004) 167-182
23. Safren S.A., Sprich S., Chulvick S., and Otto M.W. Psychosocial treatments for adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am 27 (2004) 349-360
24. Secnik K., Swensen A., and Lage M.J. Comorbidities and costs of adult patients diagnosed with attention-deficit hyperactivity disorder. Pharmacoeconomics 23 (2005) 93-102
25. Senn S. Crossover Trials in Clinical Research (1993), John Wiley & Sons, Chicester, West Sussex, United Kingdom
26. Simpson P.M., Wesnes K.A., and Christmas L. A computerized system for assessment of drug-induced performance changes in young, elderly or demented populations. Br J Clin Pharmacol 27 (1989) 711-712
27. Spencer T. ADHD treatment across the life cycle. J Clin Psychiatry 65 (2004) 22-26
28. Spencer T., Biederman J., Wilens T., Faraone S., Prince J., Gerard K., et al. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 58 (2001) 775-782
29. Spencer T., Biederman J., Wilens T., Prince J., Hatch M., Jones J., et al. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 155 (1998) 693-695
30. Wilens T., Biederman J., Spencer T., and Prince J. Pharmacotherapy of adult attention deficit/hyperactivity disorder. A review. J Clin Psychopharmacol 15 (1995) 270-279
31. Wilens T., Faraone S.V., and Biederman J. Attention-deficit/hyperactivity disorder in adults. JAMA 292 (2004) 619-623
32. Wilens T.E., Biederman J., Spencer T.J., Bostic J., Prince J., Monuteaux M.C., et al. A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder. Am J Psychiatry 156 (1999) 1931-1937